ABSTRACT

Introduction

The burden of pneumococcal disease in older UK adults remains substantial. Higher valency pneumococcal conjugate vaccines (PCVs) are currently in development with adult formulations for two of these anticipated to become available in 2022. This article collates and reviews relevant candidate data now available that may be used to support cost effectiveness assessments of vaccinating immunocompetent UK adults aged ≥65-years with PCVs.

Areas covered

This article uses published data from surveillance systems, randomized controlled trials and observational studies. It focuses on local data from the UK but where these are either limited or not available relevant global data are considered.

Expert opinion

The body of relevant data now available suggests the UK is well placed to assess the cost effectiveness of vaccinating immunocompetent ≥65-year olds with new generation higher valency PCVs. Recent contemporary data provide important new and robust insights into the epidemiology of pneumococcal disease in older UK adults and help to address much of the uncertainty and data gaps associated with previous analyses. Using these data to make informed decisions about use of new higher valency PCVs for routine use in older adults will be important for public health in the UK.

中文翻译：

---

回顾当前数据以支持在英国为免疫能力强的老年人引入下一代更高价肺炎球菌结合疫苗的决策

摘要

介绍

英国老年人肺炎球菌疾病的负担仍然很大。更高价肺炎球菌结合疫苗 (PCV) 目前正在开发中，其中两种疫苗的成人配方预计将于 2022 年上市。本文整理和回顾了目前可用的相关候选数据，这些数据可用于支持对免疫能力强的英国成人进行疫苗接种的成本效益评估年龄≥65 岁的 PCV。

涵盖的领域

本文使用来自监测系统、随机对照试验和观察性研究的已发表数据。它侧重于来自英国的本地数据，但如果这些数据有限或不可用，则会考虑相关的全球数据。

专家意见

目前可获得的相关数据表明，英国处于评估用新一代更高效价 PCV 为免疫功能正常的≥65 岁人群接种疫苗的成本效益方面处于有利地位。最近的当代数据为英国老年人肺炎球菌病的流行病学提供了重要的新的和强有力的见解，并有助于解决与先前分析相关的许多不确定性和数据差距。使用这些数据就老年人常规使用新的更高价 PCV 做出明智的决定对于英国的公共卫生非常重要。